Michael Nauck

Summary

Affiliation: Diabeteszentrum Bad Lauterberg
Country: Germany

Publications

  1. doi request reprint Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 56:1878-83. 2013
  2. pmc A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks
    Michael A Nauck
    Diabetes Center, Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes Care 36:2126-32. 2013
  3. doi request reprint Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
    M Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 15:204-12. 2013
  4. doi request reprint Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    Ann Intern Med 157:767-75. 2012
  5. doi request reprint The design of the liraglutide clinical trial programme
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes Obes Metab 14:4-12. 2012
  6. doi request reprint Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    M A Nauck
    Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Int J Clin Pract 63:46-55. 2009
  7. pmc Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
    Michael Nauck
    Diabeteszentrum Bad Lauterberg, Harz, Germany
    Diabetes Care 32:84-90. 2009
  8. ncbi request reprint A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
    M A Nauck
    Diabetes Center, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 50:259-67. 2007
  9. doi request reprint Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits
    Michael Nauck
    Diabeteszentrum, Kirchberg 21, Bad Lauterberg im Harz, Germany
    Postgrad Med 121:5-15. 2009
  10. pmc Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial
    Michael A Nauck
    Diabetes Centre, Bad Lauterberg, Germany
    Diabetes Care 34:2015-22. 2011

Collaborators

Detail Information

Publications41

  1. doi request reprint Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 56:1878-83. 2013
    ....
  2. pmc A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks
    Michael A Nauck
    Diabetes Center, Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes Care 36:2126-32. 2013
    ..In the counterpoint narrative provided below, Dr. Nauck provides a defense of incretin-based therapies and that benefits clearly outweigh any concern of risk...
  3. doi request reprint Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
    M Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 15:204-12. 2013
    ..To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes...
  4. doi request reprint Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas
    Michael A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    Ann Intern Med 157:767-75. 2012
    ..Use of an "amended" insulin-glucose ratio that accounts for the normal variation in insulin secretion according to prevailing glycemia may improve diagnostic accuracy...
  5. doi request reprint The design of the liraglutide clinical trial programme
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes Obes Metab 14:4-12. 2012
    ....
  6. doi request reprint Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    M A Nauck
    Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Int J Clin Pract 63:46-55. 2009
    ..5 and 25 mg in combination with metformin in patients whose HbA(1c) levels were inadequately controlled on metformin alone...
  7. pmc Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
    Michael Nauck
    Diabeteszentrum Bad Lauterberg, Harz, Germany
    Diabetes Care 32:84-90. 2009
    ..The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy...
  8. ncbi request reprint A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
    M A Nauck
    Diabetes Center, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 50:259-67. 2007
    ..The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart...
  9. doi request reprint Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits
    Michael Nauck
    Diabeteszentrum, Kirchberg 21, Bad Lauterberg im Harz, Germany
    Postgrad Med 121:5-15. 2009
    ..To examine the options for add-on therapy in patients with type 2 diabetes whose disease is no longer adequately controlled by lifestyle interventions and oral antidiabetic drug (OAD)monotherapy...
  10. pmc Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial
    Michael A Nauck
    Diabetes Centre, Bad Lauterberg, Germany
    Diabetes Care 34:2015-22. 2011
    ..We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy...
  11. doi request reprint Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications
    Michael A Nauck
    Bad Lauterberg Diabetes Center, Bad Lauterberg im Harz, Germany
    Am J Med 124:S3-18. 2011
    ..The results of recent head-to-head trials are reviewed, comparing the effects of incretin-based therapies on a range of clinical parameters, including glycemia, β-cell function, weight, and cardiovascular function...
  12. ncbi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
    M A Nauck
    Diabeteszentrum Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 9:194-205. 2007
    ..To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A(1c) (HbA(1c)) > or = 6.5 and < or = 10%] on metformin monotherapy...
  13. ncbi request reprint Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
    M A Nauck
    Diabeteszentrum, Bad Lauterberg im Harz, Germany
    Exp Clin Endocrinol Diabetes 114:417-23. 2006
    ..Effects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes...
  14. ncbi request reprint The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431, Bad Lauterberg, Harz, Germany
    Diabetologia 50:2413-6. 2007
  15. ncbi request reprint [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease]
    M A Nauck
    Diabeteszentrum Bad Lauterberg
    Dtsch Med Wochenschr 130:1091-6. 2005
  16. doi request reprint Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetologia 54:10-8. 2011
    ..Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake...
  17. ncbi request reprint The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
    M A Nauck
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, 37431, Bad Lauterberg im Harz, Germany
    Diabetologia 48:608-11. 2005
  18. ncbi request reprint Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
    M A Nauck
    Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg im Harz, Germany
    Horm Metab Res 36:852-8. 2004
    ..For more long-term metabolic control, incretin mimetics (agonists at the GLP-1 receptor) with more favourable pharmacokinetic profiles should be used...
  19. pmc Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    J J Meier
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Heart 90:9-12. 2004
    ..Myocardial ischaemia can also develop during emergency or elective angioplasty and during coronary bypass surgery. Therefore discontinuation of sulfonylurea treatment should be considered in these circumstances...
  20. ncbi request reprint A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome
    M A Nauck
    Diabetes Center Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg in Harz, Germany
    Acta Diabetol 40:163-72. 2003
    ..A metabolic syndrome should certainly be diagnosed if three components are present, although even in the presence of only two components, an elevated risk is evident...
  21. pmc GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes
    Nikolaos Mentis
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes 60:1270-6. 2011
    ..We studied whether GIP can alter the insulinotropic or glucagonostatic activity of GLP-1 in type 2 diabetic patients...
  22. ncbi request reprint [Differences in insulin secretion facilitate the differential diagnosis of insulinoma and factitious hypoglycaemia]
    J J Meier
    Medizinische Universitatsklinik, Knappschaftskrankenhaus, Bochum, Germany
    Dtsch Med Wochenschr 127:375-8. 2002
    ..A 33-year-old female nurse (married; two children; BMI 30.9 kg/m2) had recurrent episodes of symptomatic hypoglycaemia over some months...
  23. ncbi request reprint Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
    D Maggs
    Medical Affairs, Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Diabetes Obes Metab 10:18-33. 2008
    ....
  24. ncbi request reprint Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791, Bochum, Germany
    Diabetologia 50:806-13. 2007
    ..secretion different after oral and during intravenous glucose administration? (2) If so, is this related to the secretion of incretin hormones? (3) Is glucagon secretion abnormal in first-degree relatives of patients with type 2 diabetes?..
  25. ncbi request reprint Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus
    M A Nauck
    , Knappschaftskrankenhaus Bochum, Germany
    Horm Metab Res 29:411-6. 1997
    ..4-8.5 mmol/l). In conclusion, GLP-1 is able to normalize plasma glucose in all type 2-diabetic patients studied. This analysis underlines the great therapeutic potential of GLP-1...
  26. ncbi request reprint Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance
    R Ritzel
    Department of Internal Medicine, Ruhr-University, Knappschafts-KH, Bochum, Aarhus, Germany
    Diabetes 50:776-84. 2001
    ..Together, these results suggest a normalization of the pulsatile pattern of insulin secretion by GLP-1, which supports the future therapeutic use of GLP-1-derived agents...
  27. ncbi request reprint Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
    J J Meier
    Medizinische Klinik, , Knappschafts-Krankenhaus, Bochum (Langendreer, Germany
    Diabetes 50:2497-504. 2001
    ..In conclusion, a reduced insulinotropic activity of GIP is typical for a substantial subgroup of normoglycemic first-degree relatives of patients with type 2 diabetes, pointing to an early, possibly genetic defect...
  28. ncbi request reprint Combined pancreas and kidney transplantation in a lean type 2 diabetic patient. Effects on insulin secretion and sensitivity
    C Pox
    Department of Medicine, Ruhr University Bochum, Knappschafts Krankenhaus Bochum Langendreer, Germany
    Exp Clin Endocrinol Diabetes 110:420-4. 2002
    ..It was our aim to test the consequences of pancreas transplantation in a Type 2 diabetic patient by determining insulin secretion and sensitivity before and after surgery...
  29. ncbi request reprint Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
    J J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Diabetologia 46:798-801. 2003
    ..Therefore, we studied the effect of GIP on glucagon secretion under normoglycaemic conditions...
  30. ncbi request reprint Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers
    S Meier
    Medizinische Universitäts Klinik, Knappschafts Krankenhaus Bochum, Klinikum der Ruhr Universitat Bochum, Germany
    Horm Metab Res 35:551-6. 2003
    ..Memory effects exist for glucose and sulfonylureas. It is not known whether there is a B-cell memory for incretin hormones such as GLP-1...
  31. ncbi request reprint Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA)
    J J Meier
    Department of Medicine, Knappschafts Krankenhaus, Ruhr University, Bochum, Germany
    Exp Clin Endocrinol Diabetes 111:344-50. 2003
    ..Patients with type 2 diabetes show a significantly higher mortality after acute myocardial infarction than non-diabetic patients. The influence of sulfonylureas on the survival after acute myocardial infarction is still under debate...
  32. ncbi request reprint GIP as a potential therapeutic agent?
    J J Meier
    Larry Hillblom Islet Research Center, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Horm Metab Res 36:859-66. 2004
    ..Therefore, therapeutic strategies based on either augmenting or antagonising GIP action are far from being established alternatives for the future therapy of type 2 diabetes or obesity...
  33. ncbi request reprint alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients
    K Hucking
    Medizinische Universitatsklinik, Knappschaftskrankenhaus Bochum Langendreer Germany
    Diabet Med 22:470-6. 2005
    ..The aim of this study was to investigate the possible influence of acarbose on GLP-1 release and gastric emptying in Type 2 diabetic patients after a mixed test meal...
  34. ncbi request reprint Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Bochum, Germany
    Diabetologia 48:1872-81. 2005
    ..The secretion of GIP and GLP-1 was assessed following oral glucose ingestion...
  35. pmc To be or not to be--an incretin or enterogastrone?
    M Horowitz
    University of Adelaide, Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia
    Gut 55:148-50. 2006
    ..Glucagon-like peptide 1 does not comfortably fulfil the criterion of a gut derived factor responsible for an enhanced meal related insulin response; it appears logical to add the definition of a "physiological incretin hormone"...
  36. ncbi request reprint Preserved GLP-1 effects in a diabetic patient with Cushing's disease
    R A Ritzel
    Department of Internal Medicine, Ruhr University, Knappschafts Krankenhaus, Bochum, Germany
    Exp Clin Endocrinol Diabetes 115:146-50. 2007
    ..His diabetic state disappeared (2 h plasma glucose after 75 g oral glucose 159 mg/dl=IGT) after successful pituitary surgery (normal 24 h urinary cortisol excretion and adequate cortisol suppression with 2 mg dexamethasone)...
  37. ncbi request reprint Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile
    A Hoffmeister
    Department of Internal Medicine II-Cardiology, University of Ulm, Ulm, Germany
    Arterioscler Thromb Vasc Biol 21:427-32. 2001
    ..These lipid alterations could explain, at least in part, the reported weak association between chronic HP infection and atherosclerotic diseases...
  38. ncbi request reprint Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University, Bochum, Germany
    Diabetologia 49:452-8. 2006
    ..Exogenous glucagon-like peptide 1 (GLP-1) lowers postprandial glycaemia predominantly by slowing gastric emptying. Therefore, the effects of GLP-1 on postprandial lipid levels and gastric emptying were assessed...
  39. ncbi request reprint Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lispro-insulin for insulinoma diagnostic
    N Roudovitch
    Division of Endocrinology Department of Medicine, Clinic B. Franklin, Free University of Berlin, Germany
    Exp Clin Endocrinol Diabetes 109:397-401. 2001
    ..Direct measurement of peripheral insulin may be more sensitive than C-peptide to detect low levels of autonomous insulin secretion in small insulinomas...
  40. ncbi request reprint [Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction]
    J J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gemany
    Dtsch Med Wochenschr 127:1123-9. 2002
    ..This study was undertaken to determine whether this is also true for impaired glucose tolerance in immediate temporal relation with an acute myocardial infarction (AMI)...
  41. ncbi request reprint Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236-2240
    J J Meier
    Diabetologia 49:607-8; author reply 609-10. 2006